Patents Assigned to OncoResponse, Inc.
  • Human CD163 antibodies and uses thereof
    Patent number: 11827715
    Abstract: Provided herein are antibodies and methods of use thereof. The antibodies as disclosed herein bind to CD163+ on cells, such as on macrophages. These antibodies can be used in methods of treatment, such as methods of treating cancer.
    Type: Grant
    Filed: April 22, 2021
    Date of Patent: November 28, 2023
    Assignee: OncoResponse, Inc.
    Inventors: Kamal D. Puri, Siddarth Chandrasekaran, Melissa L. Conerly, Randi M. Simmons, Tyrel T. Smith, Mark E. Branum, Peter Probst
  • Immunomodulatory antibodies and methods of use thereof
    Patent number: 11634501
    Abstract: Provided herein are antibodies and methods of use thereof. The antibodies as disclosed herein bind to CD163+ on cells, such as on macrophages. These antibodies can be used in methods of treatment, such as methods of treating cancer.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: April 25, 2023
    Assignee: OncoResponse, Inc.
    Inventors: Kamal D. Puri, Siddarth Chandrasekaran, Melissa L. Conerly, Peter Probst, Tyrel T. Smith, Mark E. Branum, Randi M. Simmons
  • Immunomodulatory antibodies and methods of use thereof
    Patent number: 11034770
    Abstract: Provided herein are antibodies and methods of use thereof. The antibodies as disclosed herein bind to CD163+ on cells, such as on macrophages. These antibodies can be used in methods of treatment, such as methods of treating cancer.
    Type: Grant
    Filed: July 22, 2020
    Date of Patent: June 15, 2021
    Assignee: OncoResponse, Inc.
    Inventors: Kamal D. Puri, Siddarth Chandrasekaran, Melissa L. Conerly, Randi M. Simmons, Tyrel T. Smith, Mark E. Branum, Peter Probst